Physician profile
Thomas S Samuelson
NPI 1376571091
$383.75
in general payments reported to CMS, 2019-2025
12 companies · $37.42 in 2025
The $37.42 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.81 · 2020: $43.92 · 2021: $34.48 · 2022: $48.71 · 2023: $65.70 · 2024: $95.71 · 2025: $37.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $65.70 | 2023 | |
| Ferring Pharmaceuticals INC. | $65.23 | 2022-2024 | Euflexxa |
| Zimmer Biomet Holdings, INC. | $57.81 | 2019 | |
| Bioventus LLC | $35.04 | 2022-2024 | Exogen Ultrasound Bone Healing System |
| Baudax Bio INC. | $34.48 | 2021 | |
| Skeletal Dynamics INC | $30.00 | 2024 | Geminus, Ijs, Align |
| Ani Pharmaceuticals, INC. | $22.54 | 2025 | Purified Cortrophin Gel |
| Depuy Synthes Sales INC. | $16.55 | 2020 | |
| Pacira Therapeutics, INC. | $15.36 | 2020 | |
| Fidia Pharma USA INC. | $14.88 | 2025 | Hymovis, Triluron |
| Pacira Pharmaceuticals Incorporated | $14.15 | 2024 | Iovera, Zilretta |
| Janssen Biotech, INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Samuelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.